Engineered KCNA1 Gene for Stable Epilepsy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for epilepsy, particularly for focal neocortical epilepsy, face challenges in achieving stable and predictable transgene expression and safety, with existing methods showing limited efficacy in reducing seizure frequency and risk of damaging eloquent brain regions.
Innovation Solution
Development of an engineered KCNA1 gene encoding an edited Kv1.1 potassium channel, packaged in a lentiviral vector, which is designed to enhance translation and activity, and is specifically expressed in neurons using a cell-type specific promoter to reduce seizure frequency by dampening neuronal excitability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral vectors are used to deliver potassium channel genes to the brain, then transgene expression can be achieved, but stable and predictable expression with safety remains difficult to accomplish
Solution Approach 1:
The patent applies preliminary action by pre-optimizing the KCNA1 gene sequence with codon optimization and adding specific regulatory elements (Kozak sequence, polyadenylation signals) before vector construction. This preparatory optimization ensures stable and predictable expression once the gene is delivered by the viral vector, reducing the complexity of subsequent troubleshooting and improving reliability of transgene expression.
Solution Approach 2:
The patent employs parameter changes by modifying the gene sequence parameters (codon usage, GC content, regulatory element sequences) to optimize expression characteristics. These parameter adjustments enable the gene to be expressed reliably across different viral vector systems and brain regions, while the standardized optimization protocols reduce the complexity of vector design and selection.
2Reliability
If potassium channel gene therapy is applied broadly, then seizure frequency may be reduced, but the risk of damaging eloquent brain regions increases
Solution Approach 1:
The patent applies local quality by using cell-type specific promoters (such as CaMK2A promoter for excitatory neurons or GAD67 promoter for inhibitory neurons) that restrict potassium channel expression to specific neuronal populations in eloquent brain regions. This ensures that seizure control is achieved through targeted modulation of specific cell types, minimizing the risk of disrupting other critical functions in those brain regions.
Solution Approach 2:
The patent employs segmentation by dividing the brain into functional regions and further into specific cell types, then delivering the gene therapy selectively to target regions using stereotactic injection techniques. The cell-type specific promoters further segment the expression within the injected region, ensuring that only relevant neuronal populations are modified, thereby reducing the risk of harmful effects on eloquent areas.
3Ease of operation
If conventional gene therapy approaches are used, then treatment can be administered, but efficacy in reducing seizure frequency is limited
Solution Approach 1:
The patent applies composite materials by combining the KCNA1 gene with specifically designed regulatory elements (enhancers, promoters, intronic sequences) and delivering it through optimized viral vector constructs. This composite gene therapy approach creates a more effective therapeutic molecule that achieves better seizure control compared to conventional approaches, while the modular design maintains ease of administration through standard viral vector delivery protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered KCNA1 gene significantly reduces seizure frequency and inter-ictal spiking in preclinical trials, demonstrating improved safety and efficacy by targeting specific cell types and reducing the risk of exacerbating seizure activity.
Implementation Method 1
packaged in a lentiviral vector, which is designed to enhance translation and activity
Implementation Method 2
Potassium ion channels normally reduce the propensity of neurons to fire and to release neurotransmitters
Data Source
AI summary
The invention provides expression vectors, nucleic acids, vector particles and methods of treatment involving these vector particles, comprising an engineered KCNA1 gene encoding an edited Kv1.1 potassium channel, as well as methods of confirming the presence of engineered KCNA1 mRNA in a cell. The features of the engineered KCNA1 gene combine to advantageously enhance the translation and activity of the Kv1.1 protein and improve detection of KCNA1 gene expression in a cell and can be used for example in the treatment of epilepsy and similar neurological disorders.